This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Hernexeos (zongertinib)
General Description
Hernexeos (zongertinib) is a targeted prescription medicine developed for the treatment of adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) that carries specific HER2 (ERBB2) gene mutations. It is designed to help patients whose cancer is driven by HER2 alterations by targeting the underlying molecular pathway responsible for tumor growth.
Getting Talvey (talquetamab-tgvs) in India
Hernexeos (zongertinib) is an innovative targeted therapy approved in select international markets, including the United States, but is not currently commercially available in India.
Eligible patients may access Hernexeos (zongertinib) through the Named Patient Program (NPP), which enables physicians to request treatment for patients with unmet medical needs.
MitoGENE assists patients, caregivers, and healthcare professionals with documentation, regulatory requirements, import coordination, and delivery logistics, ensuring access is managed in compliance with applicable regulations and under the supervision of the treating physician.
If you or a loved one has been diagnosed with HER2-mutated non-small cell lung cancer (NSCLC) and your doctor considers Hernexeos (zongertinib) a suitable option, MitoGENE can help you explore legal access pathways..
Disease Indications: Lung Cancer
Usage: Oral
Medicine Approved by:
- Food and Drug Administration (FDA)
- Pharmaceuticals and Medical Devices Agency (PMDA)
Available Dosage Form & Package:
- A bottle with 60 tablets x 60 mg
Shipping: Room Temperature Shipping. This medicine is shipped using standard transportation methods with a controlled room temperature range of 15°C to 25°C maintained during transit. Appropriate packaging and handling procedures are used to help preserve the medicine’s quality and stability throughout the shipping process.
Four Simple Steps to Access Hernexeos (zongertinib)
If Hernexeos (zongertinib) is not yet approved or available commercially in your country, MitoGENE can help you access it through a legal pathway. Here’s how:
